HAYWARD, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--To speed development of a potential ground-breaking therapy for Type 2 diabetes – a debilitating and deadly disease that currently affects almost 350 million people worldwide – Intarcia Therapeutics, Inc., and Quintiles today announced the signing of definitive agreements whereby Quintiles will become a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).
